Physician-Led · Peer-Reviewed · APOE ε4-Specific
Your genome is not
your fate.
Act on the science.
About 1 in 4 people of European ancestry carry at least one copy of the APOE ε4 allele — the strongest known genetic risk factor for late-onset Alzheimer’s disease. Get physician-curated guidance that turns the latest research into steps you can take.
|
45%
of dementia worldwide linked to
14 modifiable risk factors |
23–30%
Alzheimer’s risk to age 85
ε3/ε4 carriers (men–women) |
65
median age symptoms
begin, ε4/ε4 carriers |
100%
Physician-authored
content |
Livingston et al., Lancet (2024) · Genin et al., Mol Psychiatry (2011) · Fortea et al., Nature Medicine (2024)
Who This Is For
Built for every stakeholder in the APOE ε4 journey
|
⚕️
Physicians & CliniciansEvidence-based frameworks for clinical care Peer-reviewed summaries, genotype-stratified risk protocols, and practical decision frameworks to elevate your care of APOE ε4-positive patients. Clinical articles → |
🧠
Patients & FamiliesUnderstand your risk. Build your plan. Clear, jargon-free explanations written by a physician who carries the gene himself — covering what APOE ε4 means for your brain, your body, and your future. Start learning → |
🔬
The Research-MindedSynthesis of the most impactful studies We track NEJM, Lancet Neurology, JAMA, Nature Medicine, and Cell Metabolism — and synthesize the findings that matter most for APOE ε4 carriers. Browse research → |
Find your path
Where are you on this journey?
Select the description that fits you best.
We will point you to the resources most relevant to your situation.
You or a loved one has been diagnosed with mild cognitive impairment, mild dementia, or moderate dementia — and you want to understand what comes next.
You may carry the APOE ε4 gene — whether confirmed by testing or suspected from family history — and you have no symptoms yet. You’re here because early action matters.
You’re caring for someone living with cognitive decline — as a family member, friend, or healthcare provider — and you need clear, practical guidance.
APOE4 Insights Premium
Go Deeper. The Full Evidence Base,
For All Three Paths.
Premium membership unlocks complete clinical reviews, evidence tables graded by study type, dual-audience articles written for both patients and clinicians, and new peer-reviewed content published weekly — by a neurologist and pain medicine specialist who carries APOE ε4 himself.
Physician-led · Evidence-grounded · No ads · No industry funding
The Biology
APOE ε4 raises risk. Risk is not destiny.
The ApoE4 isoform is associated with less efficient amyloid-β clearance, greater tau pathology, disrupted brain lipid homeostasis, and heightened neuroinflammation — mechanisms established largely in cell and animal models. In the anti-amyloid trials CLARITY AD and TRAILBLAZER-ALZ 2, ε4 carriers — especially homozygotes — had higher rates of ARIA, and the ongoing AHEAD 3-45 trial is testing whether treating amyloid before symptoms begin changes the course of disease.
For most carriers, APOE ε4 raises risk without determining outcome. In cohort studies, cardiovascular health, sleep, diet, insulin sensitivity, and cognitive reserve are associated with lower dementia risk. In the US POINTER randomized trial, a structured lifestyle program improved cognition equally in carriers and non-carriers — though no trial has yet shown that lifestyle change removes the genotype effect.
Liu et al., Nat Rev Neurol (2013) · Raulin et al., Mol Neurodegeneration (2022) · van Dyck et al., NEJM (2023) · Sims et al., JAMA (2023) · Baker et al., JAMA (2025)
Lifetime Alzheimer’s Risk by APOE Genotype
| All genotypes |
|
11–14% |
| ε3/ε4 |
|
23–30% |
| ε4/ε4 |
|
51–68% see note |
Cumulative risk of clinical Alzheimer’s disease to age 85; ranges are men–women. European-ancestry cohorts, Rochester (USA) incidence data.
Genin et al., Mol Psychiatry (2011).
A note on ε4/ε4. Clinical risk estimates to age 85 range from about 51% to 68% (Genin et al., 2011), but a single percentage describes this genotype poorly. Fortea et al. (Nature Medicine, 2024) proposed that ε4/ε4 is a distinct genetic form of Alzheimer’s disease: nearly all homozygotes show Alzheimer’s pathology, nearly all have abnormal cerebrospinal fluid amyloid by age 65, and the median age at symptom onset is 65.1 years. That classification is debated — critics argue that a common risk variant should not be grouped with autosomal dominant Alzheimer’s disease — and the question remains open.
What You Get
Rigorously sourced. Immediately applicable.
|
01
Physician-authored exclusivelyWritten and reviewed by a board-certified neurologist with subspecialty training in pain medicine and a Master of Public Health — no ghostwriters, no wellness influencers. |
02
Peer-reviewed sources onlyWe cite NEJM, Lancet Neurology, JAMA, Nature Medicine, Cell Metabolism, and Alzheimer’s & Dementia. We never cite wellness blogs, podcasts, or social media as evidence. |
03
Genotype-stratified guidanceε3/ε4 and ε4/ε4 carriers face meaningfully different risk trajectories. We address the biology and strategy specific to each genotype. |
|
04
Timely research synthesisThe field moves fast. Trial readouts, biomarker developments, and mechanistic findings are translated into practical language promptly after publication. |
05
Actionable lifestyle protocolsCardiovascular optimization, dietary fat composition, sleep architecture, insulin sensitivity, cognitive reserve — interventions with quantified effect sizes from the strongest available evidence. |
06
Independent of industryNo pharmaceutical sponsorship. No supplement affiliates. Funded by memberships and reader donations. Guidance driven by the evidence and the mission. |
|
Physician-Scientist · APOE ε4 Carrier Double Board Certified · |
About the Author “Knowledge of your genotype is not a sentence — it is a starting point.” As a neurologist and APOE ε4 carrier with a deep family history of dementia, Dr. Brian Paquette has dedicated his practice to translating the most current peer-reviewed science into actionable, compassionate guidance. Training first as a US Naval Flight Surgeon instilled a discipline for high-stakes decision-making under uncertainty — a framework that translates directly to complex cognitive neurology. Brian Paquette, DO, MPH · Neurologist · Indianapolis, Indiana Read my full story → |
Editorial Standards
How this material is produced.
Every claim published here is traceable to a specific, peer-reviewed primary source. These are not aspirations — they are the operating rules under which every article is written.
|
01 — Sourcing Peer-reviewed primary literature onlyCitations are drawn from NEJM, Lancet, JAMA, Nature Medicine, Brain, and Alzheimer’s & Dementia. Wellness blogs, podcasts, and secondary reporting are never cited as sources. |
02 — Verification Independently confirmed before publicationEvery figure is checked against the indexed source record. A claim that cannot be independently verified is removed entirely — never softened, never hedged into print. |
03 — Correction Superseded evidence is retired, not defendedWhen newer data overturn a prior position, the article is revised and the change noted. Obsolete risk figures still circulating elsewhere are corrected here explicitly. |
04 — Independence No industry funding, no affiliate revenueNo pharmaceutical sponsorship, no supplement partnerships, no advertising. Memberships and reader donations are the only funding sources — which is precisely what protects the analysis. |
Written and reviewed by Brian Paquette, DO, MPH — board-certified in neurology and pain medicine, former US Naval Flight Surgeon, and an APOE ε4 carrier. No ghostwriters.
Membership
Knowledge is the most powerful intervention.
|
Free Forever Explorer$0 No cost, always
|
Most Popular
Full Access Premium$12 per month, or $129 per year · 7-day free trial
|
You don’t have to navigate this alone
The science exists. The guidance is here. The time is now.
Whether you’ve just received your genetic results or have spent years searching for reliable answers — this platform was built for you, by a physician who carries the same gene.
|
APOE4 Insights Physician-led, evidence-based guidance for people with one or two copies of the APOE ε4 allele. Bridging the gap between genomic science and the patients, families, and clinicians navigating Alzheimer’s risk. |
Resources |
Site |
This website is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Content is intended to supplement, not replace, the physician-patient relationship. Always consult a qualified healthcare provider regarding any medical condition or treatment decision.
© 2026 APOE4 Insights